Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEDI5083 alone or in combination in advanced solid tumors
NCT03089645Phase 1Completed
- Sponsor
- MedImmune
- Start
- Mar 2017
- Primary completion
- Jun 2020
- Modality
- Fc-Fusion Proteins
- Countries
- 2
01
Overview
Phase 1, randomised, open-label trial of MEDI5083 in solid tumor (advanced stage) (4 arms), sponsored by MedImmune. Primary endpoints: Number of participants with Adverse Events (AEs), Number of participants with Serious Adverse Events (SAEs) and 5 more. Started Mar 2017; status: completed.
02
Drugs
MEDI5083
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT03089645.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03089645.